NCT07083687View on ClinicalTrials.gov

Lorlatinib in ROS1+ NSCLC With Brain Metastasis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 15, 2025

Primary Completion Date

January 1, 2027

Study Completion Date

December 1, 2028

Conditions
Lung Cancer (NSCLC)
Interventions
DRUG

Lorlatinib 100 mg

After enrollment, patients will receive 100 mg of lorlatinib orally once daily until disease progression, unacceptable toxicity, or withdraw study .

All Listed Sponsors
lead

Hunan Cancer Hospital

OTHER